Tyrogenex, a Florida biopharmaceutical company developing an oral medication for macular degeneration, is in the midst of a $12 million fundraise, according to a regulatory filing. It centers on increasing the potency, while mitigating the toxicity, of tyrosine kinase inhibitors.
The startup says its lead compound, X-82, is thought to target the basic mechanisms of neovascular eye disease.Working by inhibiting two growth factor receptors – VEGFR and PDGFR – the company’s testing X-82 in wet AMD, renal cell carcinoma, pancreatic neuroendocrine tumors and advanced solid tumors.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The reason Tyrogenex is using a compound for both wet AMD and cancer because both diseases, the company says, stem from the uncontrolled growth of blood cells.
The wet AMD phase 2 trial is being held at 22 clinical sites in the U.S. and five in the U.K.